Cargando…

Out of the shadow of interleukin-17A: the role of interleukin-17F and other interleukin-17 family cytokines in spondyloarthritis

PURPOSE OF REVIEW: The last decade has witnessed tremendous advances in revealing an important role for the interleukin (IL)-17 cytokine family in the pathogenesis of spondyloarthritis (SpA). Although most attention has been focused on IL-17A, a potential role of other IL-17 family members in inflam...

Descripción completa

Detalles Bibliográficos
Autor principal:	Yeremenko, Nataliya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	SPONDYLOARTHROPATHIES INCLUDING PSORIATIC ARTHRITIS: Edited by Joerg Ermann
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183488/ https://www.ncbi.nlm.nih.gov/pubmed/34001692 http://dx.doi.org/10.1097/BOR.0000000000000805

Ejemplares similares

Go or no-go for treat-to-target in axial spondyloarthritis?
por: Webers, Casper, et al.
Publicado: (2023)

Polyfunctional, Proinflammatory, Tissue‐Resident Memory Phenotype and Function of Synovial Interleukin‐17A+CD8+ T Cells in Psoriatic Arthritis
por: Steel, Kathryn J. A., et al.
Publicado: (2020)

Phase II Study of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17A–Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate
por: Mease, Philip J., et al.
Publicado: (2018)

Interleukin‐17A Is Produced by CD4+ but Not CD8+ T Cells in Synovial Fluid Following T Cell Receptor Activation and Regulates Different Inflammatory Mediators Compared to Tumor Necrosis Factor in a Model of Psoriatic Arthritis Synovitis
por: Xu, Xiaofei, et al.
Publicado: (2020)

Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis
por: den Braanker, Hannah, et al.
Publicado: (2020)

Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials
por: Sweet, Kristen, et al.
Publicado: (2021)

Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis
por: McInnes, Iain B., et al.
Publicado: (2021)

Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression
por: Watad, Abdulla, et al.
Publicado: (2020)

Same, same or different? Commonalities and differences between spondyloarthritis and its subsets of axial and peripheral spondyloarthritis with psoriatic arthritis and its diverse phenotypes
por: Proft, Fabian, et al.
Publicado: (2023)

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study
por: Mease, Philip J, et al.
Publicado: (2020)

Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis
por: Cardner, Mathias, et al.
Publicado: (2023)

Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?
por: Braun, Juergen, et al.
Publicado: (2023)

Extent of axial damage in psoriatic arthritis and spondyloarthritis: comparative data from the BEPAS and (Be-)GIANT multicentre cohorts
por: de Hooge, Manouk, et al.
Publicado: (2023)

Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis
por: McInnes, Iain B., et al.
Publicado: (2022)

Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J, et al.
Publicado: (2018)

IL-17 in spondyloarthritis: is the T-party over?
por: Yeremenko, Nataliya, et al.
Publicado: (2011)

Mechanistic rationales for targeting interleukin-17A in spondyloarthritis
por: Raychaudhuri, Siba P., et al.
Publicado: (2017)

Association of genetic polymorphism of interleukin-17A & interleukin-17F with susceptibility of psoriasis
por: Kaur, Rajinder, et al.
Publicado: (2018)

Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease
por: Krawiec, Paulina, et al.
Publicado: (2020)

Application of machine learning in the diagnosis of axial spondyloarthritis
por: Walsh, Jessica A., et al.
Publicado: (2019)

Targeting the Interleukin-23/Interleukin-17 Inflammatory Pathway: Successes and Failures in the Treatment of Axial Spondyloarthritis
por: Wang, Runsheng, et al.
Publicado: (2021)

The Interleukin-17 Family of Cytokines in Breast Cancer
por: Fabre, Joseph Antoine Salvator, et al.
Publicado: (2018)

The Interleukine-17 Cytokine Family: Role in Development and Progression of Spondyloarthritis, Current and Potential Therapeutic Inhibitors
por: Davydova, Anna, et al.
Publicado: (2023)

The role of Interleukin-17A and Interleukin-17E in multiple myeloma patients
por: Lemancewicz, Dorota, et al.
Publicado: (2012)

Interleukin-17A and interleukin-23 in morphea
por: Dańczak-Pazdrowska, Aleksandra, et al.
Publicado: (2012)

Interleukin-17–producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers
por: Nistala, Kiran, et al.
Publicado: (2008)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
por: Helliwell, Philip S, et al.
Publicado: (2022)

Association of interleukin-4 and interleukin-17F polymorphisms in periodontitis in Dravidian ethnicity
por: Jain, Nidhi, et al.
Publicado: (2013)

Structural basis of receptor sharing by interleukin 17 cytokines
por: Ely, Lauren K., et al.
Publicado: (2009)

Cytokine Expression of Microscopic Colitis Including Interleukin-17
por: Park, Eunkyoung, et al.
Publicado: (2015)

Interleukin-17A: The Key Cytokine in Neurodegenerative Diseases
por: Chen, Junjue, et al.
Publicado: (2020)

Interleukin-17 Family Cytokines in Metabolic Disorders and Cancer
por: Meehan, Eileen Victoria, et al.
Publicado: (2022)

Expansion of Interleukin‐22– and Granulocyte–Macrophage Colony‐Stimulating Factor–Expressing, but Not Interleukin‐17A–Expressing, Group 3 Innate Lymphoid Cells in the Inflamed Joints of Patients With Spondyloarthritis
por: Blijdorp, Iris C. J., et al.
Publicado: (2019)

Interleukin-17–targeted treatment in patients with spondyloarthritis and associated cardiometabolic risk profile
por: Queiro, Rubén, et al.
Publicado: (2023)

Targeting interleukin-17 receptors
por: Lee, Wen-Hwa, et al.
Publicado: (2015)

Roles of interleukin-17 in uveitis
por: Guedes, Marta Catarina Esteves, et al.
Publicado: (2016)

Interleukin-17 in Antifungal Immunity
por: Sparber, Florian, et al.
Publicado: (2019)

Interleukin 35 regulates interleukin 17 expression and T helper 17 in patients with proliferative diabetic retinopathy
por: Yan, Ai, et al.
Publicado: (2022)

Variable roles of interleukin-17F in different cancers
por: Mikkola, Tiina, et al.
Publicado: (2022)

Interleukin-17 and Interleukin-10 Association with Disease Progression in Schizophrenia
por: Chenniappan, Raghavi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6d1a2hlnbocq3uuanjcgmm3k2t